Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended March 31, 2026
Business Overview: A global developer, manufacturer, and marketer of medical devices used in interventional medical specialties, organized into two reportable segments: MedSurg and Cardiovascular.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $5,203 | $4,663 |
| Gross Profit | $3,614 | $3,210 |
| Gross Margin | 69.4% | 68.8% |
| Operating Income | $1,101 | $921 |
| Net Income (Attributable to Common Stockholders) | $1,341 | $674 |
| Diluted EPS | $0.90 | $0.45 |
| Operating Cash Flow | $348 | $541 |
| Cash and Cash Equivalents (End of Period) | $1,453 | $725 |
| Total Debt (Current + Long-term) | $11,029 | $11,436 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11.6% year-over-year, driven by operational growth of 9.4% (excluding foreign currency impacts). Growth was led by the Cardiovascular segment (+13.5%) and MedSurg segment (+7.8%).
- Profitability Surge: Net income nearly doubled (98.8% increase) primarily due to higher sales volume and a discrete tax benefit of $384 million related to a change in anticipated future tax rates for capitalized expenses.
- Expense Trends: Selling, General, and Administrative (SG&A) expenses rose 12% to $1.781 billion, while R&D expenses increased 16% to $516 million to support the product pipeline.
- Cash Flow: Operating cash flow decreased $193 million to $348 million due to increased working capital payments, despite higher operating income. Investing cash outflows increased to $591 million, largely due to the $523 million acquisition of Nalu Medical.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Acquisition Activity: The company completed the acquisition of Nalu Medical ($523 million) in Q1 2026. It has also entered definitive agreements to acquire Penumbra, Inc. (approx. $14.5 billion) and Scivita Medical (approx. $200 million upfront). The Penumbra deal is subject to regulatory review (FTC Second Request) and is expected to close in H2 2026.
- Capital Structure: In February 2026, the company secured new credit facilities, including a $3.0 billion revolving credit agreement and a $6.0 billion term loan facility to fund the Penumbra acquisition. The stock repurchase authorization was increased by $4.0 billion to a total of $5.0 billion.
- Segment Performance: Strong performance in Electrophysiology (led by Farapulse PFA System) and Interventional Cardiology (led by AGENT Drug-Coated Balloon) offset some deceleration in WATCHMAN procedures.
Risks and Contingencies
- Legal Proceedings: Ongoing product liability litigation regarding transvaginal surgical mesh and spinal cord stimulation devices. A securities class action was filed in March 2026 alleging misleading statements regarding financial guidance.
- Regulatory: The Penumbra acquisition is pending FTC approval. The company faces ongoing scrutiny regarding Foreign Corrupt Practices Act (FCPA) compliance and other regulatory inquiries.
- Macroeconomic: Exposure to foreign currency fluctuations, global trade policies, and supply chain disruptions.
Investor Verification Checklist
- Tax Rate Volatility: Verify the sustainability of the reported tax rate, which was significantly impacted by a one-time $384 million discrete tax benefit.
- Acquisition Integration: Monitor the regulatory status and closing timeline of the $14.5 billion Penumbra acquisition and its impact on future leverage ratios.
- Legal Accruals: Review the $229 million legal accrual for product liability and patent litigation to assess potential future cash outflows.
- Working Capital: Analyze the decline in operating cash flow relative to net income, driven by increases in receivables and inventory.
- Debt Covenants: Confirm continued compliance with the 4.25x leverage ratio covenant, which is elevated due to the prior Axonics acquisition.